CARLSBAD, Calif. / Jul 24, 2024 / Business Wire / Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced the commercial launch of EOS Insight, a groundbreaking, end-to-end spine surgery platform powered by standardized EOSedge™ scans and AI. With the first customer implementation complete, the EOS Insight-informed surgeries were successfully performed at OrthoIndy Hospital by David G. Schwartz, MD, and Craig McMains, MD.
“My first clinical experience with EOS Insight affirmed that the cutting-edge features ATEC developed can transform surgery,” asserted Schwartz. “Relying on EOS Insight, I entered surgery with an efficient, AI-driven customized plan, precise alignment measurements and rods pre-contoured for the long construct. The technology increased my confidence in the operating room. I was able to compare my progress to the pre-operative plan throughout the surgery, then perform a final reconciliation prior to its completion. EOS Insight is truly the most comprehensive spine innovation I’ve witnessed in my 35-year clinical tenure.”
EOS Insight is a cloud-based software platform that leverages the unmatched precision and capabilities of the EOSedge imaging platform and AI to deliver crucial information throughout the multiple stages of spine care. EOS Insight provides access to integrated, efficient point-of-care applications including AI-driven alignment calculation, informed 3D-surgical planning simulations, patient-specific rods, intra-operative reconciliation and post-operative patient and practice analytics. The data generated through these applications is being leveraged to fuel continued progress towards more predictable spine care.
“The debut of EOS Insight marks a pivotal moment for ATEC,” said Pat Miles, Chairman and Chief Executive Officer. “Its development harnessed unequivocal spine-focused knowhow to integrate informatics into every step of the clinical workflow. Unlike the plethora of duplicative “enabling technology” in spine, Insight modernizes surgery, replacing archaic clinical practices to improve patient outcomes. EOS Insight positions ATEC to be the standard-bearer in spine.”
Rajiv Sethi, MD, Chair of the Neuroscience Institute, Director of Spine Research and Director of Complex Spine Surgery at the Virginia Mason Medical Center in Seattle and an EOS Insight surgeon advisor, added, “By automating spine’s onerous, iterative processes, EOS Insight meets the need for standardization and objectivity in spine surgery. For example, while alignment is most correlated to successful long-term surgical outcomes, alignment measures are rarely integrated into surgical plans because they are manually calculated, an incredibly time-consuming process. Comparatively, EOS Insight calculates alignment data in minutes and integrates that data into a custom surgical plan. I even have the option to request a rod contoured precisely to the custom surgical plan. The combination of the platform’s data collection capabilities and point-of-care solutions at each stage of surgery has the potential to unleash monumental advancements in spine care.”
About EOS Insight
The EOS Insight ecosystem, built on EOSedge standardized imaging, combines comprehensive point-of-care solutions, a cloud-based user portal, and advanced AI capabilities to enhance clinical decision-making throughout the surgical experience. The initial feature set will include the following:
About Alphatec Holdings, Inc.
ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC’s Organic Innovation MachineTM is focused on developing new approaches that integrate seamlessly with the Company’s expanding AlphaInformatiX Platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. ATEC’s vision is to be the Standard Bearer in Spine. For more information, visit us at www.atecspine.com.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. A list and description of such risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.
Last Trade: | US$9.35 |
Daily Change: | 0.50 5.65 |
Daily Volume: | 1,702,336 |
Market Cap: | US$1.330B |
December 09, 2024 October 30, 2024 September 18, 2024 July 29, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB